Ratings Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-08 EDT			5-day change	1st Jan Change
322.50 ^USD	+1.13%		+0.45%	-2.93%

06-24	Barclays Initiates Coverage on Medpace With Equal Weight Rating, $300 Price Target	MT
04-28	Medpace Holdings Insider Sold Shares Worth $516,716, According to a Recent SEC Filing	MT

Summary: Medpace Holdings, Inc.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Highlights: Medpace Holdings, Inc.

The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: Medpace Holdings, Inc.

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The firm trades with high earnings multiples: 25.01 times its 2025 earnings per share.
The company's enterprise value to sales, at 4.01 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings Chart: Medpace Holdings, Inc.

Source: Surperformance

ESG chart: Medpace Holdings, Inc.

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	MEDPACE HOLDINGS, INC.				9.17B
	LONZA GROUP AG				49.47B
	CELLTRION, INC.				28.87B
	BEONE MEDICINES LTD.				28.55B
	IQVIA HOLDINGS INC.				28.1B
	EUROFINS SCIENTIFIC SE				12.68B
	ICON PUBLIC LIMITED COMPANY				11.73B
	QIAGEN N.V.				10.29B
	Average				22.36B
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

BBB

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes